Articles related to Endocrinology, Diabetes, Metabolism

Mayim Bialik reports prolonged gastrointestinal symptoms after one dose of an unnamed GLP-1 medication taken for autoimmune symptoms. Her account describes individual intolerance, not the frequency of severe reactions or evidence of autoimmune benefit.

In a prospective cohort of more than 112,000 French adults, higher intake of several commonly used food preservatives was associated with increased risks of hypertension and cardiovascular disease, though the observational design cannot determine whether the additives themselves caused the observed outcomes.

In a secondary analysis of 371,038 U.S. adults, individuals reporting several cardiovascular disease (CVD) risk factors or established CVD reported less frequent whole-fruit consumption. The cross-sectional survey identified associations only and did not establish whether dietary behaviors preceded disease.

In a large multinational target-trial emulation, adults with serious mental illness who initiated GLP-1 receptor agonists experienced lower mortality and cardiovascular event rates than matched patients initiating SGLT2 inhibitors, though residual confounding remains a key limitation.

Nearly one in six pediatric GLP-1 receptor agonist users received a nutritional-deficiency or related diagnosis within one year, while nutrition counseling remained limited and generally occurred months after treatment initiation.

A case report describes duodenal ulcer perforation in a woman receiving tirzepatide for weight loss, occurring shortly after dose escalation, though important confounders prevent conclusions about a causal drug relationship.